The Kærtor Foundation launched in the summer of 2017 a call for expressions of interest, focused on adding value to biomedical research from the I2D2 (Incubation Innovation in Drug Discovery) program. The foundation wanted to contribute in this way to the discovery of drugs for diseases without therapeutic solutions, supporting the best biomedical science on the mechanisms of the disease. A de-risking strategy will be applied to drug discovery programs, leaping over in this way the gap towards its industrial application.
Kærtor Foundation call for Expressions of interest
If you are a researcher specializing in disease mechanisms and want to apply your research to drug discovery, we would like to collaborate with you. We already know how to accelerate early drug discovery using the Kærtor methodology, creating a parallel path to your research without interfering with it. The potential publication of your research lines will not be affected by this parallel drug discovery process but may even be promoted by the synergies created with the new tools applied. The only confidentiality in the process is that associated with candidate drug molecules themselves.
In our methodology, a steering committee is created, which you will join, and we open a channel of communication in real time that allows research, although driven in parallel, to be receptive and permeable to the progress of each one.
The call is sponsored by the Janssen pharmaceutical company, which participates in the selection and monitoring of those programs within the areas of interest without acquiring any IP rights.
After the incubation and maturation stages, Janssen will have a right of first negotiation/license on the programs.
The expressions of interest received will be reviewed by the Kærtor Foundation experts and the evaluation committees to build a prioritized pipeline of selected programs.
They will be selected for development on the basis of their level of innovation and the stage of progress of the program in the drug discovery process